194 related articles for article (PubMed ID: 12432437)
41. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
42. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
43. [Darbepoetin in the treatment of the renal anaemia in the patient undergoing peritoneal dialysis previously treated with epoetin alfa].
Remón C; Quirós P; Fernández Marchena D; Hernández Romero M; del Castillo R; Fernández Ruiz E
Nefrologia; 2005; 25(2):170-7. PubMed ID: 15912654
[TBL] [Abstract][Full Text] [Related]
44. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
[TBL] [Abstract][Full Text] [Related]
45. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.
Cheung WK; Goon BL; Guilfoyle MC; Wacholtz MC
Clin Pharmacol Ther; 1998 Oct; 64(4):412-23. PubMed ID: 9797798
[TBL] [Abstract][Full Text] [Related]
47. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
Hymes J; Bickimer T; Jackson JH; Bookhart BK; Mody SH; Tak Piech C
Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
[TBL] [Abstract][Full Text] [Related]
48. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S;
Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st Communication: A monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers.
Kirkov V; Dimitrova V; Siebert-Weigel M; Wolf-Pflugmann M; Koytchev R; Richter W; Bronn A; Arsova S; Kromminga A
Arzneimittelforschung; 2008; 58(5):215-9. PubMed ID: 18589555
[TBL] [Abstract][Full Text] [Related]
50. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
51. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
Toto RD; Pichette V; Navarro J; Brenner R; Carroll W; Liu W; Roger S
Am J Nephrol; 2004; 24(4):453-60. PubMed ID: 15331889
[TBL] [Abstract][Full Text] [Related]
52. The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep.
McLennan DN; Porter CJ; Edwards GA; Heatherington AC; Martin SW; Charman SA
Pharm Res; 2006 Sep; 23(9):2060-6. PubMed ID: 16951999
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.
Macdougall IC; Gray SJ; Elston O; Breen C; Jenkins B; Browne J; Egrie J
J Am Soc Nephrol; 1999 Nov; 10(11):2392-5. PubMed ID: 10541299
[TBL] [Abstract][Full Text] [Related]
54. The advantages of intravenous renal anaemia treatment in an undernourished patient with chronic kidney disease.
Shiell KA; McKane W; Wilkie M
Curr Med Res Opin; 2003; 19(6):481-4. PubMed ID: 14594519
[TBL] [Abstract][Full Text] [Related]
55. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.
Paganini EP; Eschbach JW; Lazarus JM; Van Stone JC; Gimenez LF; Graber SE; Egrie JC; Okamoto DM; Goodkin DA
Am J Kidney Dis; 1995 Aug; 26(2):331-40. PubMed ID: 7645538
[TBL] [Abstract][Full Text] [Related]
56. Intravenous administration of darbepoetin to NICU patients.
Warwood TL; Ohls RK; Lambert DK; Jones C; Scoffield SH; Gupta N; Veng-Pedersen P; Christensen RD
J Perinatol; 2006 May; 26(5):296-300. PubMed ID: 16554846
[TBL] [Abstract][Full Text] [Related]
57. Darbepoetin alfa: a new therapeutic agent for renal anemia.
Macdougall IC
Kidney Int Suppl; 2002 May; (80):55-61. PubMed ID: 11982814
[TBL] [Abstract][Full Text] [Related]
58. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
Egrie JC; Dwyer E; Browne JK; Hitz A; Lykos MA
Exp Hematol; 2003 Apr; 31(4):290-9. PubMed ID: 12691916
[TBL] [Abstract][Full Text] [Related]
59. Single-dose darbepoetin administration to anemic preterm neonates.
Warwood TL; Ohls RK; Wiedmeier SE; Lambert DK; Jones C; Scoffield SH; Neeraj G; Veng-Pedersen P; Christensen RD
J Perinatol; 2005 Nov; 25(11):725-30. PubMed ID: 16151471
[TBL] [Abstract][Full Text] [Related]
60. Clinical experience with darbepoetin-alfa (Aranesp).
Locatelli F; Del Vecchio L; Marai P
Contrib Nephrol; 2002; (137):403-7. PubMed ID: 12101985
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
